Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized caplacizumab regimen based on ADAMTS13 monitoring in adult acquired TTP
2020-005288-30Phase 2Terminated
- Sponsor
- Rouen University Hospital
- Start
- Nov 2020
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of caplacizumab in thrombotic thrombocytopenic purpura (TTP), sponsored by Rouen University Hospital. Primary endpoint: Composite endpoint at 30 days post-plasma exchange. Started Nov 2020; status: terminated.
02
Drugs
caplacizumab
03
Conditions
thrombotic thrombocytopenic purpura (TTP)
Beyond the preview
Go deeper on 2020-005288-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005288-30.